Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Pretransplant Risk Factors for Calcineurin Inhibitor-Induced Encephalopathy and Limbic Encephalitis Following Allogeneic Hematopoietic Cell Transplantation

Nao Tanizawa, MD, Hideo Koh, MD PhD, Hiroshi Okamura, MD PhD, Koh Shiro, MD PhD, Satoru Nanno, MD PhD, Mitsutaka Nishimoto, MD PhD, Asao Hirose, MD PhD, Mika Nakamae, MD PhD, Yasuhiro Nakashima, MD PhD, Takahiko Nakane, MD PhD, Masayuki Hino, MD PhD, Hirohisa Nakamae, MD PhD

Blood (2019) 134 (Supplement_1): 4492.

https://doi.org/10.1182/blood-2019-124264

Published: 2019

Journal Articles

Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)

Jennifer R. Brown, MD PhD, Matthew S. Davids, MD, Julie E Chang, MD, Shuo Ma, MD PhD, Juliana M L Biondo, MD, Yong Mun, PhD, Madlaina Breuleux, PhD, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 4320.

https://doi.org/10.1182/blood-2019-123665

Published: 2019

Journal Articles

Incidence of Thromboembolic Disease in Hereditary Hemorrhagic Telangiectasia (Osler Weber Rendu Syndrome)

Marcelo Martin Serra, MD, Cristina Maria Elizondo, MD, Marina Alonso, MD, Veronica Peuchot, MD, Fernando Javier Vazquez, PhD

Blood (2018) 132 (Supplement 1): 4967.

https://doi.org/10.1182/blood-2018-99-112945

Published: 2018

Journal Articles

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Richard Leblanc, MD FRCPC, Imran Ahmad, MD MPH, Rafik Terra, PhD, Séverine Landais, PhD, Céline Nkoue, MD, Michael Sebag, MD PhD, Émilie Lemieux Blanchard, MD FRCPC, Nadia M. Bambace, MD, Léa Bernard, MD, Sandra Cohen, MD FRCP(C), Jean-Sébastien Delisle, MD PhD, Thomas L. Kiss, MD, Silvy Lachance, MD FRCP, Denis-Claude Roy, MD, Guy Sauvageau, MD, PhD, Jean Roy, MD

Blood (2018) 132 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2018-99-112313

Published: 2018

Journal Articles

Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, MD PhD, Matthew S Davids, Julie Chang, Shuo Ma, MD PhD, Juliana Biondo, Mehrdad Mobasher, MD MPH, Yong Mun, PhD, Anthony R Mato, MD

Blood (2018) 132 (Supplement 1): 5556.

https://doi.org/10.1182/blood-2018-99-116942

Published: 2018

Journal Articles

Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia

Benjamin L. Lampson, MD PhD, Haesook T Kim, PhD, Matthew S. Davids, MD, Jeremy S. Abramson, MD MMSc, Arnold S. Freedman, MD, Caron A. Jacobson, MD, Philippe Armand, MD PhD, Robin M. Joyce, MD, Jon E. Arnason, MD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, Samantha Huang, Joshua Fein, John Hanna, Stacey Marie Fernandes, BS, David C. Fisher, MD, Jennifer R. Brown, MD PhD

Blood (2017) 130 (Supplement 1): 1734.

https://doi.org/10.1182/blood.V130.Suppl_1.1734.1734

Published: 2017

Journal Articles

Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical Study

Peter Hillmen, Anna Schuh, MD PhD, Toby A. Eyre, MD, John M. Pagel, MD PhD, Jennifer R. Brown, MD PhD, Paolo Ghia, John N. Allan, MD, William Wierda, MDPhD, Ahmed Hamdy, MBBCh, Jane Huang, MD, Raquel Izumi, PhD, Priti Patel, Min Hui Wang, John C. Byrd, MD

Blood (2016) 128 (22): 60.

https://doi.org/10.1182/blood.V128.22.60.60

Published: 2016

Journal Articles

Lesions of the Central Nervous System in Leukemia: Pathologic and Magnetic Resonance Imaging (MRI) Features in 14 Patients

Jing Liu, Yaming Wang, Xuefei Sun, Jun Qian, Shuo Liu, Zhenkun Yu, Nan Ji, Shengjun Sun, Yuanbo Liu

Blood (2015) 126 (23): 4878.

https://doi.org/10.1182/blood.V126.23.4878.4878

Published: 2015

Journal Articles

Infections Associated with Bendamustine – a Retrospective Multicenter Study

Anat Gafter-Gvili, MD, Elena Ribakovsky, MD, Nadav Mizrahi, Abraham Avigdor, MD, Ariel Aviv, MD, Liat Vidal, MDMSc, Ron Ram, MD, Arnon Nagler, MD, Pia Raanani, MD, Ronit Gurion, MD

Blood (2014) 124 (21): 3077.

https://doi.org/10.1182/blood.V124.21.3077.3077

Published: 2014

Journal Articles

Analysis of Major Infection Risk in 706 Patients with Chronic Lymphocytic Leukemia

Andrea Visentin, MD, Nicolò Compagno, MD, Monica Castelli, MD, Francesco Cinetto, MD, Renato Zambello, MD, Francesco Piazza, MD, Giampietro Semenzato, MD, Carlo Agostini, MD, Livio Trentin, MD

Blood (2014) 124 (21): 3321.

https://doi.org/10.1182/blood.V124.21.3321.3321

Published: 2014

Journal Articles

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)

Francesc Bosch, MD, PhD, Pau Abrisqueta, Neus Villamor, MD. PhD, María José Terol, MD, PhD, Eva González-Barca, MD, Marcos González, MD, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A. Garcia-Marco, MD, PhD, Yolanda Gonzalez, Felix Carbonell, MD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, Ana Muntanola, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD. PhD

Blood (2011) 118 (21): 293.

https://doi.org/10.1182/blood.V118.21.293.293

Published: 2011

Journal Articles

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM).

Francesc Bosch, MD, PhD, Neus Villamor, Pau Abrisqueta, MD, María José Terol, Eva González-Barca, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A Garcia-Marco, MD, PhD, Yolanda Gonzalez, Felix Carbonell, MD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, MD, Ana Muntanola, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD

Blood (2010) 116 (21): 1382.

https://doi.org/10.1182/blood.V116.21.1382.1382

Published: 2010

Journal Articles

Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405

Blood (2010) 116 (21): 2471.

https://doi.org/10.1182/blood.V116.21.2471.2471

Published: 2010

Journal Articles

A Two Step Myeloablative Approach to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Hematological Malignancies From HLA Partially-Matched (Haploidentical) Related Donors.

Dolores Grosso, DNP, Matthew Carabasi, MD, Janet Brunner, PA-C, Beth Colombe, PhD, Joanne Filicko-O'Hara, MD, Eileen C Finnegan, CRNP, Phyllis Flomenberg, MD, Margaret Kasner, MD, Bijoyesh Mookerjee, MD, William O'Hara PharmD, Nyree Tedesco-Garafano, CRNP, John L. Wagner, MD, Maria Werner-Wasik, MD, Neal Flomenberg, MD, FACP

Blood (2009) 114 (22): 2292.

https://doi.org/10.1182/blood.V114.22.2292.2292

Published: 2009

Journal Articles

Effective Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning for Patients with Chronic Granulomatous Disease.

Yoko Mizoguchi, MD, Mizuka Miki, MD, Teruyuki Kajiume, MD, Hiroshi Kawaguchi, MD, Kazuhiro Nakamura, MD, Takashi Sato, MD, Masao Kobayashi, MD, PhD

Blood (2009) 114 (22): 3339.

https://doi.org/10.1182/blood.V114.22.3339.3339

Published: 2009

Journal Articles

Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study

Blood (2008) 112 (11): 3167.

https://doi.org/10.1182/blood.V112.11.3167.3167

Published: 2008

Journal Articles

Successful Bone Marrow Transplantation with an Intensively Immunosuppressive Conditioning with Low Toxicity for High-Risk Chronic Granulomatous Disease Patients.

Mizuka Miki, MD, Teruyuki Kajiume, M.D., Kazuhiro Nakamura, M.D., Hiroshi Kawaguchi, M.D., Takashi Sato, M.D., Emi Kurita, Rie Onodera, Asako Hiraoka, Tomoyuki Mizukami, M.D., Hiroyuki Nunoi, M.D., Masao Kobayashi, M.D.

Blood (2006) 108 (11): 5354.

https://doi.org/10.1182/blood.V108.11.5354.5354

Published: 2006

Journal Articles

Infusion of Microbially Contaminated Hematopoietic Cell Products Has No Adverse Effect on Clinical Outcome.

Poliaa A. Patah, MD, Simrit Parmar, MD, Marcos de Lima, MD, Tara Sadeghi, BS, Safa Karandish, BS, John McMannis, PhD, Gabriela Rondon, MD, Jeffrey Tarrand, MD, Richard Champlin, MD, Elizabeth J. Shpall, MD

Blood (2006) 108 (11): 3387.

https://doi.org/10.1182/blood.V108.11.3387.3387

Published: 2006

NARROW

Pretransplant Risk Factors for Calcineurin Inhibitor-Induced Encephalopathy and Limbic Encephalitis Following Allogeneic Hematopoietic Cell Transplantation

Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)

Incidence of Thromboembolic Disease in Hereditary Hemorrhagic Telangiectasia (Osler Weber Rendu Syndrome)

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia

Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical Study

Lesions of the Central Nervous System in Leukemia: Pathologic and Magnetic Resonance Imaging (MRI) Features in 14 Patients

Infections Associated with Bendamustine – a Retrospective Multicenter Study

Analysis of Major Infection Risk in 706 Patients with Chronic Lymphocytic Leukemia

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM).

Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405

A Two Step Myeloablative Approach to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Hematological Malignancies From HLA Partially-Matched (Haploidentical) Related Donors.

Effective Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning for Patients with Chronic Granulomatous Disease.

Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study

Successful Bone Marrow Transplantation with an Intensively Immunosuppressive Conditioning with Low Toxicity for High-Risk Chronic Granulomatous Disease Patients.

Infusion of Microbially Contaminated Hematopoietic Cell Products Has No Adverse Effect on Clinical Outcome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only